In this issue:
- ctDNA predicts response to neoadjuvant chemoradiotherapy
- Capecitabine vs active monitoring in mCRC
- Open vs laparoscopic surgery in mid and low rectal cancer
- WEE1 inhibition in TP53- and RAS-mutant mCRC
- Rectal cancer treatment and outcomes in elderly patients
- Robotic-assisted total mesorectal excision for rectal cancer
- Nivolumab plus ipilimumab in mCRC
- Panitumumab in RAS wild-type mCRC
- TAS-116 plus nivolumab in patients with CRC
- Biomarkers of immune checkpoint inhibition in MMR-deficient CRC
Please login below to download this issue (PDF)